FDA Reaffirms Digoxin Products for Oral Use, Sets Marketing Conditions

Summary

The US Food and Drug Administration (FDA) is reaffirming its status as a new drug for digoxin products available in tablet and elixir form, and outlining the requirements for manufacturers to market these products, including submitting new drug applications (NDAs) or abbreviated new drug applications (ANDAs).